Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a high risk of metastasis and therapeutic resistance. These issues are closely linked to the tumour microenvironment (TME) surrounding the tumour tissue. The association between residing TME components with tum...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-12-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/1/112 |
| _version_ | 1797437882391068672 |
|---|---|
| author | Rafia Ali Huimin Shao Pegah Varamini |
| author_facet | Rafia Ali Huimin Shao Pegah Varamini |
| author_sort | Rafia Ali |
| collection | DOAJ |
| description | Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a high risk of metastasis and therapeutic resistance. These issues are closely linked to the tumour microenvironment (TME) surrounding the tumour tissue. The association between residing TME components with tumour progression, survival, and metastasis has been well elucidated. Focusing on cancer cells alone is no longer considered a viable approach to therapy; thus, there is a high demand for TME targeting. The benefit of using nanoparticles is their preferential tumour accumulation and their ability to target TME components. Several nano-based platforms have been investigated to mitigate microenvironment-induced angiogenesis, therapeutic resistance, and tumour progression. These have been achieved by targeting mesenchymal originating cells (e.g., cancer-associated fibroblasts, adipocytes, and stem cells), haematological cells (e.g., tumour-associated macrophages, dendritic cells, and myeloid-derived suppressor cells), and the extracellular matrix within the TME that displays functional and architectural support. This review highlights the importance of nanotechnology-based therapeutics as a promising approach to target the TME and improve treatment outcomes for TNBC patients, which can lead to enhanced survival and quality of life. The role of different nanotherapeutics has been explored in the established TME cell-driven populations. |
| first_indexed | 2024-03-09T11:28:05Z |
| format | Article |
| id | doaj.art-fb789aeb32f2447996057af43bcc768a |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-09T11:28:05Z |
| publishDate | 2022-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-fb789aeb32f2447996057af43bcc768a2023-11-30T23:57:49ZengMDPI AGPharmaceutics1999-49232022-12-0115111210.3390/pharmaceutics15010112Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven PopulationsRafia Ali0Huimin Shao1Pegah Varamini2School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, AustraliaSchool of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, AustraliaSchool of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, AustraliaTriple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with a high risk of metastasis and therapeutic resistance. These issues are closely linked to the tumour microenvironment (TME) surrounding the tumour tissue. The association between residing TME components with tumour progression, survival, and metastasis has been well elucidated. Focusing on cancer cells alone is no longer considered a viable approach to therapy; thus, there is a high demand for TME targeting. The benefit of using nanoparticles is their preferential tumour accumulation and their ability to target TME components. Several nano-based platforms have been investigated to mitigate microenvironment-induced angiogenesis, therapeutic resistance, and tumour progression. These have been achieved by targeting mesenchymal originating cells (e.g., cancer-associated fibroblasts, adipocytes, and stem cells), haematological cells (e.g., tumour-associated macrophages, dendritic cells, and myeloid-derived suppressor cells), and the extracellular matrix within the TME that displays functional and architectural support. This review highlights the importance of nanotechnology-based therapeutics as a promising approach to target the TME and improve treatment outcomes for TNBC patients, which can lead to enhanced survival and quality of life. The role of different nanotherapeutics has been explored in the established TME cell-driven populations.https://www.mdpi.com/1999-4923/15/1/112tumour microenvironmentnanoparticlestriple negative breast cancertargetingtumour progressionmetastasis |
| spellingShingle | Rafia Ali Huimin Shao Pegah Varamini Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations Pharmaceutics tumour microenvironment nanoparticles triple negative breast cancer targeting tumour progression metastasis |
| title | Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations |
| title_full | Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations |
| title_fullStr | Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations |
| title_full_unstemmed | Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations |
| title_short | Potential Nanotechnology-Based Therapeutics to Prevent Cancer Progression through TME Cell-Driven Populations |
| title_sort | potential nanotechnology based therapeutics to prevent cancer progression through tme cell driven populations |
| topic | tumour microenvironment nanoparticles triple negative breast cancer targeting tumour progression metastasis |
| url | https://www.mdpi.com/1999-4923/15/1/112 |
| work_keys_str_mv | AT rafiaali potentialnanotechnologybasedtherapeuticstopreventcancerprogressionthroughtmecelldrivenpopulations AT huiminshao potentialnanotechnologybasedtherapeuticstopreventcancerprogressionthroughtmecelldrivenpopulations AT pegahvaramini potentialnanotechnologybasedtherapeuticstopreventcancerprogressionthroughtmecelldrivenpopulations |